Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384624 | 1.00 | PPARA (0.47) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL6337223 | 1.00 | PPARA (0.47) | PPARAPPARGCTSKCTSSACE | |
| Benzene SCHEMBL28847299 | 0.97 | PPARA (0.51) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL617475 | 0.92 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL2564729 | 0.92 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL617476 | 0.92 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL2726974 | 0.91 | CTSK (0.51) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL211798 | 0.91 | CTSK (0.51) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL211797 | 0.91 | CTSK (0.51) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL22283971 | 0.90 | CTSK (0.46) | PPARAPPARGCTSKCTSSACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | CELGENE CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4590673-A1 | FLUORESCENT PROBES FOR MAGL | F. Hoffmann-La Roche AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| EP-4584258-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4543892-A1 | FLUORESCENT PROBES FOR MAGL | F. Hoffmann-La Roche AG (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-119192183-A | Benzodiazepines class of compounds and uses thereof | 中国药科大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| CN-101478972-A | Haloaryl substituted aminopurines, compositions thereof, and methods of using same in therapy | SIGNAL PHARM LLC (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-2074108-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008036247-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036216-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| CN-101142215-A | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2008-03-12 | — | — | CN | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| CN-1578767-A | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PPARA 3521/4885PPARG 3804/4885CTSK 863/4885 |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | IKZF1, IKZF3, IKZF2 | PPARA 4241/4885PPARG 3909/4885CTSK 3369/4885 |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | PPARA 4313/4885PPARG 2988/4885CTSK 676/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | PPARA 776/4885PPARG 1348/4885CTSK 3995/4885 |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | PPARA 3976/4885PPARG 3852/4885CTSK 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.